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Breast tumour tissues of both animals and man
contain a receptor system for oestrogen. Oestrogen
combines with a high affinity receptor in the
cytoplasm of the target cell and the complex is
transferred to the nucleus from where the metabolic
response of the tissue is directed (De Sombre, 1982;
Jordan, 1982). In the past decade significant
advances in the treatment of breast cancer were
made after it was discovered that tumours could be
classified as oestrogen-receptor (ER)-rich or ER-
poor. This classification correlated with the
response of the tumour during treatment by
hormonal manipulation; ER-poor tumours did not
respond whereas from 50-60% of ER-rich tumours
did (Henderson & Canellos, 1980; De Sombre,
1982). Thus the assay of tumour cytosols has
become an important tool for the clinician to help
in the assessment of treatment protocols. The drugs
used for the treatment of breast cancer can be
divided into 2 broad categories: One comprises the
hormonally-related drugs which includes
diethylstilboestrol and the antioestrogen tamoxifen.
The other group includes an alkylating agent,
cyclophosphamide, the antimetabolites,
methotrexate and 5-fluoruracil and the antibiotic
adriamycin, which are usually administered in the
form of combined intermittent therapy (Henderson
& Cannelos, 1980). It is well established that the
oestrogen agonists and antagonists will react with
the ER system (Leclercq & Heuson, 1979). Recently
it was demonstrated that 2 non-steroidal
antimetabolites used for the treatment of breast
cancer would also interact with the ER system of
the rat uterus (Di Carlo et al., 1978). Methotrexate
and adriamycin were shown to competitively
prevent the binding of oestradiol-17,B to the
receptor in vitro. In vivo changes were also
produced which suggested that these drugs reacted
with the receptor system in a manner similar to
oestrogen. These somewhat surprising results have
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important implications for breast cancer
management. Treatment of a patient with these
drugs prior to tumour biopsy could produce a false
negative on a receptor screen or may even alter the
response of a tumour to subsequent hormonal
manipulation. However, if these drugs were acting
via the ER system then a novel rationale for the use
of receptor-directed cytotoxic drugs could be
formulated with possibilities for improvement in the
treatment of breast cancer. The antibiotic
actinomycin D and cycloheximide have been used
to investigate the role of protein synthesis in the
establishment of tissue receptor levels (Cidlowski &
Muldoon, 1978; Dix & Jordan, 1980; Horwitz &
McGuire, 1980). As the results of Di Carlo et al.
(1978) raised the possibility that they also may react
directly with the receptor system, they have been
included in this investigation, with tamoxifen and a
variety of antimetabolites and antibiotics of
markedly different molecular structures.
Immature female Sprague-Dawley rats (20-25
days old), bred in the Medical School, were used for
the experiments. Drugs were administered i.v. via
the tail vein dissolved in 0.2ml of 0.9% w/v sodium
chloride. Rats were killed by decapitation and the
uteri dissected and rapidly cooled in ice cold buffer
before weighing and homogenisation. [3H]-
oestradiol-17 ,B (Sp. Act. - 85CimM-1) was
obtained from the Radiochemical Centre,
Amersham, England. Oestradiol-17 ,B, actinomycin
D and cycloheximide were obtained from Sigma
Chemicals (London) Ltd, Poole, Dorset, England.
Methotrexate (powder-methotrexate USP. Potency
88.8% ampoules methotrexate for injection
20mgml-1), adriamycin (Doxrubicin hydrochloride)
and tamoxifen were gifts from Lederle Laboratories,
Gosport, Hampshire, Montedison Pharmaceutical
Ltd, New Barnet, Hertfordshire and ICI Ltd,
Macclesfield, Cheshire respectively. All other
reagents were Analar grade.
Oestrogen receptor assay (a) in vitro experiments.
Untreated rats were killed, the uteri removed and
© The Macmillan Press Ltd., 1983.434 I.D. MORRIS & T.M. STEPHEN
homogenisation, cytosol preparation and the
determination of the number of oestrogen receptors
and their affinity for oestradiol-17 ,B were carried
out as described by Ginsburg et al. (1974) with the
exception of the buffer system which is described
below. Uteri were homogenised in Tris-HCl
(0.01 M) buffer pH 7.4, containing EDTA 1 mM,
Dithiothreitol 0.5mM. Homogenates were
centrifuged at 105,000g for 1 h. Aliquots of the
supernatant fraction (cytosol) were incubated to
equilibrium at either 30°C (10min) or 4°C (18h)
with [3H]-oestradiol-17f, (4x 10-9-2x 101OM)
with and without a 100 fold excess of
diethylstilboestrol so that the oestrogen specific
binding could be determined. Non-radioactive
compounds, except methotrexate (10- M) and
tamoxifen, were added to the incubate dissolved in
10jl of buffer to give the final concentration
required. In order to achieve the high concentration
of methotrexate (10' M), this agent was dissolved
in sodium hydroxide (0.1 N). The addition of 10jul
of this solution to the incubate altered the pH from
7.4 to - pH8, therefore a vehicle control was
included in the experiments. Low concentrations of
methotrexate and other drugs did not alter the pH
of the incubate. When methotrexate was prepared
from the commercially-prepared ampoules
concentrations > I6M could not always be
achieved. Tamoxifen was added to the incubate
dissolved in ethanol, control incubates contained
ethanol alone. In experiments designed to examine
the effects of preincubation of the drug, the drug
was added to the cytosol 90min or 10min before
the [3H]-oestradiol for the 4°C or 30°C incubations
respectively. After incubation bound oestradiol was
separated from free oestradiol by the use of small
columns of Sephadex LH20 maintained at 4°C. The
radioactivity in the eluate from this and other
experiments was determined by liquid scintillation
spectrometry. The effects of each series of the drugs
and their controls were determined upon one
cytosol and the results from several cytosols taken
to give the mean and s.e. (b) in vivo experiments.
Rats were injected with drug and, when
appropriate, 5min later with oestradiol-17 ,B; the
rats were killed after 1 h. A modified method of Roy
& McEwen (1977) was used to determine
cytoplasmic and nuclear oestrogen receptors (ERc;
ERn). The method was modified by the replacement
of the phosphate buffer with 0.1 M Tris-HCI buffer,
pH 7.6 and initially homogenising the uterus in
Tris-HCl buffer, pH 7.6 containing 0.32 M sucrose,
3mM MgCl2 and 0.5mM dithiothreitol, so that a
high-speed cytosol could be prepared as outlined
above. ERn were prepared by extraction of purified
nuclei with Tris-HCl buffer pH 7.6 containing
0.4 M KCl, 0.5mM dithiothreitol and 0.05 M
Bacitracin. Aliquots of the extract were incubated
with [3H]-oestradiol-17/, (3 x 1083 x 10-10M)
for 2h at 30°C with or without a 100-fold excess of
diethylstilboestrol to determine the oestrogen-
specific binding. Separation of bound from free
oestradiol was carried out as described previously.
The assayed concentrations of specifically-bound
oestradiol in the incubate were used to construct
plots (Scatchard, 1949) from which the equilibrium
dissociation constant KD and the saturation binding
capacity were determined. Binding of [3H]-
oestradiol-17 /3 to the ER, is expressed per mg of
protein (the Lowry technique) or in terms of total
binding per uterus. The results are presented as the
mean +s.e. and the significance of the difference
between groups calculated by Mann Whitney U test
(two-tailed).
Results
The effects of incubation of a variety of drugs with
the rat uterine ERC and [3H]-oestradiol are given in
the Table. Scatchard plots were constructed for all
incubation conditions except for tamoxifen 10 6M
and methotrexate I (10-3M, preincubation, 30°C)
when specific [3H]-oestradiol binding could only be
measured in one or two of the incubates. Apparent
dissociation constants for the reaction between
[3H]-oestradiol-17# and the uterine cytosol ranged
between 0.6-10 x 10- 0M. Methotrexate, prepared
from either ampoules or powder, incubated at 4°C
or 30°C, with or without preincubation did not
change the binding of [3H]-oestradiol to the cytosol
in concentrations up to 10' M. Methotrexate at
10-3M decreased the [3H]-oestradiol binding when
compared to vehicle; in general, the changes were
small and not always significant (see Table).
Actinomycin D, adriamycin and cycloheximide
did not alter [3H]-oestradiol binding when added
to the incubates in concentrations up to 10'6 M. In
contrast tamoxifen (10'6 M) almost completely
inhibited the specific binding of [3H]-oestradiol to
the uterine cytosol.
Methotrexate and adriamycin when administered
to the rat by i.v. injection did not alter the pattern
of ER distribution in the uterus, oestradiol-17#
decreased the ERC and increased the ERn content of
the uterus (Figure). When methotrexate was
administered to the rats at the same time as
oestradiol-17,/ the uterine cytosol receptor content
was not changed; the nuclear receptor content
appeared to decrease but this change did not
achieve significance (P>0.05). The receptor
distribution after oestradiol and adriamycin was
similar to the distribution found after oestrogen
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Table I The in vitro effects ofsome non steroidal drugs upon the specific binding of[3H]-
oestradiol to cytosol prepared from immature rat uteri. The interactions were examined
at 4 or 30°C with or without preincubation as described in the methods. The
methotrexate used for the experiments, Methotrexate I and Methotrexate II, was supplied
as a powder or in commercially prepared ampoules respectively. V=alkaline vehicle
control. The results (mean +s.e.m., n=4-8) are expressed as the number of binding sites
per mg cytosol protein x 1011.
Effects ofincubation with drugs on binding of[3HJ-oestradiol to rat uterine ER,
Drug concentration (M)
0 10-9 1o-6 1o-3 V
Methotrexate I
40C 5.8+0.4 6.4+0.3 5.8+0.3 5.3+0.4 6.0+0.3
300C 4.6+1.4 5.6+1.6 5.0+1.6 2.9+1.3 5.0+1.5
Preincubation
40C 6.1+0.4 5.9+0.4 6.2+0.6 5.1+0.3 5.9+0.3
300C 3.6+0.7 3.9+0.6 3.5+0.4 1.2* 3.9+0.7
Methotrexate II
40C 6.0+0.3 5.8+0.2 6.1+0.2 5.2+0.4 ND
Preincubation
40C 5.7+0.8 5.2+0.7 5.2+0.6 ND ND
Concentration (M)
0 10-9 10-6
Adriamycin
40C 9.1+0.5 8.7+0.7 10.9+1.9
Preincubation
40C 5.0+0.7 5.8+0.7 7.8+0.7
Actinomycin D
40C 3.4+0.4 3.7+0.5 3.7+0.4
Cycloheximide
40C 5.7+1.3 5.1+1.2 5.5+1.22
Tamoxifen
40C 13.7+3.7 10.1 +2.8 5.5*
300C 3.8+ 1.0 3.6+0.6 0.4*
ND=not determined.
*Only 1 or 2 cytosols gave results which could be distinguished from diethylstilboestrol
incubates.
Significance of differences from appropriate control values *P<0.05.
The in vitro and in vivo experiments suggests that
the antibiotics actinomycin D and adriamycin, &
the antimetabolites cycloheximide and
methotrexate do not specifically react with the
oestrogen receptors. These results are in agreement
with those of Muller et al. (1980) and fail to confirm
the data of Di Carlo et al. (1978). Muller et al.
(1980) assayed oestrogen binding by saturation
analysis, employing a single oestradiol
concentration, whereas Di Carlo et al. (1978) used
multiple oestradiol concentrations and Scatchard
(1949) analysis which might have accounted for the
different results. However, our experiments
examined the binding of oestradiol-17,B under a
variety of rigidly-controlled conditions (single and
multiple oestradiol-17 ft concentration saturation
analysis, co- and pre-incubation of the competitor
and incubation at either 4°C or 30°C), yet we could
not demonstrate the high level of competition that
was shown by Di Carlo et al. (1978). Significant
changes in oestradiol-17,f binding were found only
after incubation with very high concentrations of436 I.D. MORRIS & T.M. STEPHEN
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Figure 1 The uterine content of cytosol (open bars) and nuclear (closed bars) ER determined M litro. The
uterine fractions were prepared from rats killed I h after the iL. injection of saline (C 0.2ml), methotrexcate
(M, I mg kg ') adriamycin (A. 0.5 mg kg - '), oestradiol- 1 7fI (E. 5jig) or combinations of these drugs (Mealn
±s.e., n =4 7).
methotrexate (10-M), therefore it is possible that
the inhibition of binding by these drugs of
substantially different molecular structure from the
steroids is a result of non-specific interaction. A
specific interaction was shown by the use of
tamoxifen which is well known to possess high
affinity for the ER (Dix & Jordan, 1980; Jordan,
1982). In this case a substantial reduction in the
binding of oestradiol-17fl to the receptor was
demonstrated.
The actions of oestrogens upon the target cell is
associated with a decrease in the ER, concentration
as the receptor ligand complex is translocated to
the nucleus. This response is well documented (see
for example Dix & Jordan, 1980) and has been
demonstrated in the present series of experiments.
Similar changes may have been predicted if
adriarmycin and methotrexate reacted directly with
the receptor. yet none were seen. If the reaction
with the receptor was in some way not detectable
by the current methods then these drugs, when
administered with oestradiol, would be expected to
alter the pattern of receptor changes. Once again no
change was demonstrated. These data confirm the
conclusions from the in vitro experiments that these
drugs do not react directly with ER.
Actinomycin D and cycloheximide were without
effect upon the in vitro binding of oestradiol-17/3 to
the receptor, so it is reasonable to assume that the
receptor changes reported in previous papers
(Cidlowski & Muldoon, 1978; Dix & Jordan, 1980;
Horwitz & McGuire, 1980) reflects the role of
protein synthesis in the maintenance of tissue
H.A.R. concentrations. Such experiments have led
to the conclusion that receptor concentrations are
maintained by 2 mechanisms, tle unom synthesis and
recycling. Methotrexate, adriamycin and many
other drugs used for the treatment of breast cancer
will inhibit protein synthesis, so that while the
present experiments have failed to demonstrate a
direct effect of these drugs upon ER an indirect
action via inhibition of receptor protein synthesis
cannot be discounted.
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